StockNews.com assumed coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Free Report) in a research report report published on Sunday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Trading Down 0.6 %
Shares of TTNP stock opened at $6.85 on Friday. Titan Pharmaceuticals has a fifty-two week low of $5.00 and a fifty-two week high of $16.90. The stock has a 50 day simple moving average of $7.14 and a two-hundred day simple moving average of $7.34.
Institutional Investors Weigh In On Titan Pharmaceuticals
A number of large investors have recently bought and sold shares of the stock. Virtu Financial LLC bought a new position in shares of Titan Pharmaceuticals during the 2nd quarter worth about $35,000. Millennium Management LLC boosted its holdings in Titan Pharmaceuticals by 516.8% in the second quarter. Millennium Management LLC now owns 63,106 shares of the specialty pharmaceutical company’s stock worth $35,000 after acquiring an additional 52,874 shares in the last quarter. State Street Corp acquired a new stake in Titan Pharmaceuticals in the third quarter valued at approximately $41,000. Finally, Renaissance Technologies LLC increased its holdings in shares of Titan Pharmaceuticals by 559.3% during the second quarter. Renaissance Technologies LLC now owns 240,710 shares of the specialty pharmaceutical company’s stock valued at $135,000 after acquiring an additional 204,200 shares in the last quarter. 31.49% of the stock is currently owned by institutional investors and hedge funds.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in the United States, Canada, and the European Union.
Read More
- Five stocks we like better than Titan Pharmaceuticals
- Basic Materials Stocks Investing
- MarketBeat Week in Review – 4/1 – 4/5
- Manufacturing Stocks Investing
- Beazer Homes USA is an Overlooked Opportunity in Housing
- How to Calculate Inflation Rate
- 5 Stocks in the Current Bull Market with Upside to Come
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
